



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/987,931	11/16/2001	Kevin Qun Fang	4821-439-999	7960
20582	7590	07/23/2007		
JONES DAY 222 East 41st Street New York, NY 10017-6702			EXAMINER SAMALA, JAGADISHWAR RAO	
			ART UNIT 1618	PAPER NUMBER
			MAIL DATE 07/23/2007	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

09/987,931

Applicant(s)

FANG ET AL.

Examiner

Jagadishwar R. Samala

Art Unit

1618

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 18 June 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 127, 129 and 133 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 127, 129 and 133 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date 12/11/06 & 3/21/07.
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

RCE Acknowledged

A request for continued examination (RCE) under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17 (e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17 (e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on June 18, 2007 has been entered.

Status of Application

1. Acknowledgment is made of amendment filed on June 18, 2007. Upon entering the amendment, the claims 1-126, 128 and 130-132 are cancelled and claims 127 and 129 are amended.
2. The pending claims are 127, 129 and 133 and presented for the examination.

Response to Arguments

Applicant's arguments filed on June 18, 2007 with respect to claims have been considered but are moot in view of the new ground (s) of rejection due to the scope changes made into the newly amended claims.

Claim Objection

Claim 127 is objected to because of the following informalities: there is inadvertent typographical error was found in claim 127 wherein (S, S)-2-(-3-chlorophenyl)-3,5,5-trimethyl-3-morpholinol is incorrectly typed whereas -3-morpholinol (it should be -2-morpholinol) is incorrectly spelled (see instant specification at page 2, lines 13-14). Appropriate correction is required.

Claim Rejections - 35 USC § 112

1. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

2. Claims 127, 129 and 133 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. Claims are drawn to a method of treating "affective disorder" conditions of human beings, there is no clear description and/or envision in specifications to "affective disorder" conditions in human beings. The generic terminology "affective disorder" conditions is not limited to an anxiety disorder, attention deficit disorder, attention deficit disorder with hyperactivity seasonal affective disorder and thereof. The state of art recognizes the "affective disorder" conditions as very broad, generally refers to various types of affective disorder" (e.g. generalized anxiety disorder and panic disorder, agoraphobia, avoidant personality disorder, social phobia, obsessive compulsive disorder, post-traumatic stress disorder, memory disorders including dementia, amnesic disorders and age-associated memory impairment, disorders of eating behavior and thereof) in human being.

As such, the disclosure of the instant specification is not sufficient to support the generic concept of a method of treating an "affective disorder" conditions in human being and requires further clarification.

Claim Rejections - 35 USC § 103

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

4. Claims 127, 129 and 133 are rejected under 35 U.S.C. 103(a) as being unpatentable over Morgan (US6274579, 6391875, 2003/0064988) in view of Spier (1998, abstract only, Use of bupropion with SRIs and venlafaxine).

Note: all these patents are children cases of US6274579 and disclosures therein are substantially same. Therefore, the examiner will use US'579 to represent all these cases.

The claims are drawn to a method of treating or preventing an affective disorders such as anxiety disorder, attention deficit disorder, attention deficit hyperactivity disorder (ADHD) bipolar or manic condition, depression or seasonal affective disorder by administering a therapeutically effective amount of wherein (S, S)-2-(-3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol and adjunctively effective amount of secondary active agent.

Art Unit: 1618

Morgan et al (US'579) teaches a compound (+)-(2S, 3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol and its composition used for treating depression, attention deficit hyperactivity disorder (ADHD), obesity or addiction to cocaine or nicotine containing product (e.g., tobacco), see abstract.

The critical elements required by the claims are well taught by the cited reference(s) except that they required secondary active compound such as SSRI compound.

However, it would have been obvious to one of ordinary skill in the art at that time of the invention was made to add secondary active agent when Morgan (US'579) is taken in view of Spier's reference because latter reference teaches the combination drug treatment wherein bupropion is main active agent combined with an effective amount of secondary active agent effectively used in the treatment of various affective disorders.

Spier teaches a combination drug of bupropion with SRI's and venlafaxine in the treatment of depression, see abstract. It also teaches that the drug response is superior in combination drug therapy compared to monotherapy.

Since Morgan teaches that bupropion's anti-depressant activity is resulted from the, active metabolite in vivo, i.e.. (+)-(2S, 3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol (see col. 8, lines 15-20), one would have been motivated, with reasonable expectation of success, to add SSRI compound as secondary active compound into antidepressant (i.e. (+)-(2S, 3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol) to treat affective disorders because the combination drug treatment improves efficacy by lowering side effects and achieve additive pharmacological effect because these agents are utilizing different underlying mechanisms as taught in Howard and Bertrand references. It is clearly suggested in later references that

Art Unit: 1618

combination drug treatment could enhance drug efficacy and improve industrial applicability as well. Furthermore, combination drug therapy is standard drug regimen well known in the field of psychiatry medicine, see extrinsic supporting documents PTO-892, for instance, Zarate (2003, Combination treatment in bipolar disorder).

One would have been motivated to combine these references and make the modification because they are drawn to same technical fields (constituted with same ingredients and share common utilities, and pertinent to the problem which applicant concerns about. MPEP 2141.01(a).

5. Claims 127-132 are rejected under 35 U.S.C. 103(a) as being unpatentable over Howard et al (US 5,597,826)) or Bertrand (EP 0701819) in view of Morgan et al (US8274579).

The claims are drawn to a method of treating or preventing an affective disorders such as anxiety disorder, attention deficit disorder, attention deficit hyperactivity disorder (ADHD) bipolar or manic condition, depression or seasonal affective disorder by administering a therapeutically effective amount of wherein (S, S)-2-(-3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol and adjunctively effective amount of secondary active agent.

Firstly, Howard discloses SSRI (serotonin re-uptake inhibitor) used for treating or preventing disorders arising from deficient or excessive serotonergic neurotransmission condition selected from mood disorders, including depression, seasonal affective disorders, anxiety disorders, wherein said 5-HT re-uptake inhibitor is sertraline or a pharmaceutically acceptable salt of polymorph thereof (see abstract and claim 4).

Secondly, Bertrand discloses a composition containing serotonin selective re-uptake (SSRI) and an agonist or antagonist of the serotonin 1 (5-HT) receptor for treating or preventing

Art Unit: 1618

a condition selected from mood disorders, including depression, seasonal affective disorders, anxiety disorders, wherein said 5-HT inhibitor is sertraline (see abstract).

The claims are differ in that they require bupropion's metabolite rather than bupropion itself.

As mentioned earlier,(supra), Morgan teaches that bupropion's anti-depressant activity is resulted from the active metabolite in vivo, i.e. (+)-(2S, 3S)-2-(3-chlorophenyl)- 3,5,5-trimethyl-2-morpholinol (see col. 8, lines 15-20).

In light of Morgan (US6274579) teaching, one would have been motivated, with reasonable expectation of success, to substitute bupropion with its active metabolite i.e. (+)-(2S, 3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol), and administer combination drug (i.e. SSRI or 5HT compound as secondary active compound into antidepressant (i.e., bupropion metabolite) to treat affective disorders because the metabolite is the active form where optimal drug dosage regimen can be used for determining most efficient drug treatment. Additionally combination drug treatment can be benefited by optimal dose used in the treatment because it could maximally lower side effects and furthermore, achieve additive or synergistic pharmacological effect because these agents are utilizing different underlying mechanisms as taught in Howard and Bertrand references.

All the critical elements required by the instant claims are well taught in the cited reference and thus, the claimed subject matter is not patentably distinct over the prior art of the record.

Double Patenting

6. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

7. Claims 127-132 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 13-15 and 58-78 of copending Application No. 09/987930 in view of *Spier*, *Howard* or *Bertrand* (see above in 103 rejection), both inventions are drawn to the similar invention where the scope of the invention is overlapping substantially. For the same reason set forth in 103 rejection, the claimed subject matter shared overlapping scope (i.e., a treatment of affective disorders using (2S, 3S)-2-(3-

Art Unit: 1618

chlorophenyl)-3,5,5-trimethyl-2-morpholinol) and the combination with secondary is clearly envisioned when secondary teaching is taken together.


This is a provisional obviousness-type double patenting rejection.

Conclusion

1. No claims are allowed at this time.
2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jagadishwar R. Samala whose telephone number is (571)272-9927. The examiner can normally be reached on 8.30 A.M to 5.00 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Hartley can be reached on (571)272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



Jagadishwar R Samala
Examiner
Art Unit 1618

sjr

Zohreh Fay